Gastric Cancer Registry Team Reports Major Progress in Webinar
The Gastric Cancer Registry is actively seeking new participants who have been affected by gastric cancer. Click here for more information and online enrollment.
Foundation-Funded Research Receives Major Award from DOD
Early-stage seed funding is extremely important because it enables researchers to generate sufficient preliminary data to submit compelling and competitive applications for large grants. It is often difficult for researchers to obtain this type of support. The Gastric Cancer Foundation has made early funding a special focus of its research strategy.
Spring Asparagus Salad with Lemon Yogurt Dressing

This month, Chef Hans Rueffert is sharing a recipe that celebrates Spring in the best way Hans knows how; Asparagus is nutritious, delicious, inexpensive and easy to prepare. It’s low in calories and a great source of nutrients, including fiber, folate and vitamins A, C and K.
A special note from Chef Hans: 

"I planted asparagus in my modest vegetable/herb/fruit garden several years ago, and it has finally started paying off. Every Spring I anxiously wait for the kelly-green asparagus shoots to break through ground and reward me with a dozen or so crisp stalks of deliciousness. For me, it’s not the calendar, but the asparagus that marks the beginning of Spring and it brings me joy each and every year..." Read More

Find all episodes at the Gesundheit Kitchen on gastriccancer.org.
Research Roundup
Recent advances in gastric cancer research include a groundbreaking FDA approval and more.

The FDA approved the first immunotherapy for the first-line treatment of advanced gastric cancer, Bristol Myers Squibb’s Opdivo. The approval was based on phase 3 trial data showing that combining the drug with certain types of chemotherapy improved survival over chemotherapy alone.

A study in the U.K. found that being overweight raises the risk of gastric cancer in women but not men, suggesting that weight management would be a good preventative measure in women.

In a phase 2 trial in advanced gastric cancer with high expression of the CLDN18.2 protein, adding Ganymed Pharmaceuticals’ experimental antibody drug zolbetuximab to chemotherapy improved progression-free and overall survival as compared to chemo alone.
Special Thanks to Our
National Sustaining Sponsors
Spread the word. Share the Gastric Cancer Foundation Newsletter.